top of page




Keystone Meeting on Cancer Immunotherapy Beyond Immune Checkpoint Blockade and Overcoming Resistance in Vancouver, Canada. “High Labyrinthin Expression is Associated with High PDL-1 Expression and Poor Prognosis in Patients with NSCLC”, March 2024.

Society for Immunotherapy of Cancer meeting, Nov 2023:

  1. “Labyrinthin as a potential neoantigen for oncogene-driven and non-oncogene-driven lung adenocarcinomas”; confirms labyrinthin as a diagnostic marker and a therapeutic target and reports on the novel finding that the more labyrinthin is expressed on tumors, the more that the immune checkpoint receptor, PDL-1, is expressed. The results validate Phase II clinical trial using a PDL-1 blocker (pembrolizumab) with our vaccine, LabVax.  See Full Article Here.

  2. "Novel biomarker assays for detecting labyrinthin-positive adenocarcinomas for a phase I/II trial of peptide vaccine LabVax 3(22)-23 alone or in combination with pembrolizumab”, sets that stage for the Phase II trial using LabVax and immune checkpoint inhibitor combination.  See Full Article Here.

  3. “A phase 1/2 open label study of LabVax 3(22)-23 and adjuvant GM-CSF alone or in combination with pembrolizumab in subjects with labyrinthin-positive adenocarcinomas”; describes the clinical trial.  See Full Article Here.


14th Annual World Cancer Congress in Barcelona, Spain.  “Labyrinthin:  From bench-to-clinic as neo-and pan-adenocarcinoma target.” July 2023.

Li, et al. A first-in-human phase I trial of a novel peptide vaccine LabVax 3(22)-23 and adjuvant GM-CSF sargramostim in patients with refractory labyrinthin-expressing adenocarcinomas. ASCO/Journal of Clinical Oncology 2023.

LabyRx is one of the highlighted companies at MedInvest (New York City) via National Cancer Institute
invitation; December 2022.


LabVax was selected for a special oral presentation entitled “Novel Peptide Vaccines against Labyrinthin
for Adenocarcinomas” that was given by a lead researcher at the UCD NIH-Designated Comprehensive
Cancer Center.  October 2022.

“High Labyrinthin Expression is Associated with Poor Prognosis in Patients with NSCLC” shared a novel,
yet expected, study result in which labyrinthin expression is directly related to patient morbidity (i.e.,
death). The work presented by a team of UCD investors supports the idea that labyrinthin is more than
a marker, but important to screen patients for anti-labyrinthin treatment, predict patient outcomes (Dx)
and serve as a key target in strategizing an attack on adenocarcinomas. October 2022.

W Ma, et al. A First-In-Human Phase I open-label study of a novel cancer vaccine LabVax 3(22)-23 and adjuvant GM-CSF in patients with advanced stage adenocarcinomas. American Society for Clinical Oncology (ASCO) 2022.

M Babich, T Li, JA Radosevich. Generation of peptide vaccines targeting labyrinthin, a pan-adenocarcinoma biomarker.  American Association for Cancer Research (AACR), 2020.

Saleeve, et al. Anti-labyrinthin monoclonal antibody reduces human adenocarcinoma circulating tumor cells in the blood of patient-derived xenograft models and inhibits the growth of adenocarcinoma cell cultures. AACR, 2019.


Phase II clinical trial approved by FDA…without comment!  The clinical trial is in collaboration with the University of California, Davis and the National Cancer Institute.  Building upon the Phase I clinical trial success, this Phase II will study LabVax (+GM-CSF as adjuvant) in combination with pembrolizumab, what’s referred to as a checkpoint inhibitor.  In other words, there will be an “offensive” as well as “defensive” approach to treating the cancers: LabVax (i.e., our active immunotherapy vaccine) induces the immune system attack in the cancers, whereas pembrolizumab is an FDA approved antibody that prevents cancer cell resistance., 2023.

Phase I clinical trial of LabVax is successful.  The trial was completed March 2023.  The results of this initial study were remarkably encouraging. The treatment was well tolerated and without any adverse event.

“28th Annual Cancer Research Symposium draws big crowd” CANCER CARE October 14, 2022. Our
proprietary target, Labyrinthin, was a featured subject.

Clinical Trial: A Cancer Vaccine (LabVax 3(22)-23) and GM-CSF for the Treatment of Advanced Stage Adenocarcinoma, ClinicalTrials.Gov 2021.


Topology and Adenocarcinoma Cell Localization Dataset on the Labyrinthin Diapeutic Biomarker. BMC Research Notes, 2023.

Labyrinthin Expression Is Associated with Poor Prognosis in Patients with Non-Small-Cell Lung Cancer, Cancer 2023.


Labyrinthin: A Distinct Pan-Adenocarcinoma Diagnostic and Immunotherapeutic Tumor Specific Antigen, Heliyon, 2022.

Topology and Adenocarcinoma Cell Localization Dataset on the Labyrinthin Biomarker, bioRxiv, 2022.

Labyrinthin, the Tumor Marker Recognized by MCA 44-3A6: A Case for Pan-Tumor Markers as Targets to Treat Cancer, Oncotaregts and Therapy, 2019.

Expression of the Adenocarcinoma-Related Antigen Recognized by Monoclonal Antibody 44-3A6 in Salivary Gland Neoplasias, Otolaryngology Head & Neck Surgery, 1998.

Monoclonal Antibody 44-3A6 as an Adjunct in Cytodiagnosis of Adenocarcinomas in Body Fluids, Diagnostic Cytopathology, 1992.

Changes in the Expression of the Tumor-Associated Antigen Recognized by the Monoclonal Antibody 44-3A6 in A549 Cells due to Calcium, Tumor Biology,1991.

Expression of the Epitope Recognized by the Monoclonal Antibody 44-3A6 during Human Fetal Development, Tumor Biology, 1991.

Application of Monoclonal Antibody 44-3A6 in the Cytological Diagnosis of Pleural Effusion and Histological Correlation in Lung Carcinoma, Lung Cancer, 1991.

The Use of Monoclonal Antibody 44-3A6 in Cell Blocks in the Diagnosis of Lung Carcinoma, Carcinomas Metastatic to Lung and Pleura, and Pleural Malignant Mesothelioma, American Journal Of Pathology, 1991.

Cell Cycle and Electron Microscopic Evaluation of the Adenocarcinoma Antigen Recognised by the Monoclonal Antibody 44-3A6, British J. Cancer, 1991.

Monoclonal Antibody 44-3A6 as a Marker for Breast Carcinoma, Tumor Biology, 1991.

Monoclonal Antibody 44-3A6 Doxorubicin Immunoconjugates: Comparative in vitro Anti-Tumor Efficacy of Different Conjugation, Methods Tumor Biology, 1991.

Immunohistochemical Analysis of Human Adenocarcinomas of the Lung Using the Monoclonal Antibody 44-3A6, Tumor Biology, 1989.

Expression of the Antigenic Determinant Recognized by the Monoclonal Antibody 44-3A6 on Select Human Adenocarcinomas and Normal Human Tissues, Tumor Biology, 1988.

Malignant Mesotheliomas: Improved Differential Diagnosis From Lung Adenocarcinomas Using Monoclonal Antibodies 44-3A6 and 624A12, American Journal Of Pathology, 1986.

Application of Monoclonal Antibody 44-3A6 in the Cytodiagnosis and Classification of Pulmonary Carcinomas, Diagnostic Cytopathology, 1985.

Monoclonal Antibody 44-3A6 as a Probe for a Novel Antigen Found on Human Lung Carcinomas with Glandular Differentiation, Cancer Research, 1985. 

bottom of page